Sandeep Kulkarni shares a framework from his chairman, Clay Siegall: a biotech can fail, get acquired after short-term success, get acquired after long-term success, or achieve rare 'escape velocity' to stay independent. This pragmatic view frames acquisition not as a lesser option but as a primary successful outcome for most.

The CEO of NervGen explicitly states his goal is to commercialize their spinal cord injury drug independently, not to position the company for an acquisition. This long-term, mission-driven focus on getting a drug to market shapes strategic decisions and contrasts with a common build-to-sell mentality in biotech.

Vivtex funded its growth and reached profitability not through traditional VC rounds, but by securing around 10 early pharma partnerships. This strategy provided significant non-dilutive revenue, reducing their reliance on investors and giving them more control over their trajectory—a powerful alternative to the typical biotech funding model.

A biotech transitioning from a small, 'fit-for-purpose' R&D team to a large commercial organization gets a rare chance to create a new culture. Madrigal treated its rapid growth from ~100 to over 500 people as an opportunity to establish fresh core values for the newly-formed enterprise.

In the rare disease space, success hinges on deep patient community engagement. Smaller, nimbler biotechs often excel at creating these essential personal ties, giving them a significant advantage over larger pharmaceutical companies.

Contrary to most industries, scale is not a decisive advantage in drug discovery. Wellington's Jean Hynes notes that small, nimble biotech companies discover roughly half of all new drugs. This creates a perpetual opportunity for investors to back small firms that can generate massive value.

For small biotechs, the playbook for success extends beyond scientific discovery. It requires creativity and innovation in the operational process itself—finding efficient paths through regulatory checkpoints, securing non-traditional funding, and leveraging external resources to advance development with limited capital.

The current biotech bull market is fundamentally different from past rallies. It's driven by small and mid-sized companies successfully launching products and generating revenue, shifting the sector from a "dream-based" industry to one focused on execution and profitability.

Iolyx Therapeutics' CEO notes the surprising capital efficiency of lean biotech. Her team advanced a drug from discovery through Phase 2 for approximately $20 million—an amount she could have easily spent on a single marketing campaign at Genentech. This highlights the operational leverage of focused, small teams.